AstraZeneca & AVEO Oncology Form Collaboration to Investigate Liver Cancer Immunotherapy

Dec 15, 2018 | Liver Cancer

Richard Staines of PharmaPhorum reports that global commercial sponsor AstraZeneca and AVEO Oncology have formed a partnership to develop cancer immunotherapy combination for liver cancer.  AstraZeneca is looking to combine Imfinzi, an anti PD-L1 class drug with AVEO’s Fotivda (tivozanib) in first line hepatocellular carcinoma.


Pin It on Pinterest